HighTide Therapeutics integrates expertise in disease biology, medicinal chemistry, clinical development, and regulatory affairs to develop novel therapeutics for the global markets. Several clinical trials have been completed in the United States, Australia, Canada and China.
Currently, HighTide is focusing on advancing the development of several assets. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity. HighTide’s continued clinical progress with HTD1801 includes a global Phase 2b study that has been initiated for the treatment of nonalcoholic steatohepatitis (NASH), an initiate Phase 3 study for the treatment of type 2 diabetes (T2DM), and the successful end-of-phase 2 clinical studies for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). The U.S. Food and Drug Administration (FDA) has granted HTD1801 Fast Track designation in both NASH and PSC.
New molecular entity: ionic salt of two active moieties
Peptide analog of RegIII/PAP protein active fragment
An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs
© 2023 HighTide Therapeutics Inc.